NVO - Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition | Benzinga
Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart disease than in men with the same condition.
What Happened: In a recent analysis of study data, involving 1,145 patients, centered on a condition known as heart failure with preserved ejection fraction (HFpEF). The data from these studies was shared at the American Diabetes Association’s scientific meeting in Orlando, Florida, Reuters reported on Monday.
While the drug led to similar improvements in HFpEF symptoms in both genders, women lost an average of 9.6% of their weight, compared to men who lost about 7.2% of body weight. The trials were not designed to evaluate the treatment effects of ...